~A Boy Always Young~

2014年12月24日 星期三

Subclinical hypothyroidism

For patients with subclinical hypothyroidism and TSH concentrations ≥10 mU/L, we suggest treatment with thyroid hormone (T4).

For non-older patients with TSH concentrations between 4.5 and 10 mU/L who have symptoms of hypothyroidism, we also suggest treatment with T4.

For older patients (over age 70 years) with subclinical hypothyroidism and TSH between 4.5 and 8 mU/L, we suggest "not" treating.

We recommend initiating T4 replacement in women with subclinical hypothyroidism (TSH values >2.5 mU/L) who are pregnant.
read more

2014年12月17日 星期三

Subclinical hyperthyroidism with multiple nodular goiter

Multinodular goiters was noted in our hospital in Sep. She did not compalined of any discomfort. Although operation and RAI will reduce the size of goiter and relieve symptoms, these treatment should be discussed with the patient first.

Autonomously functioning thyroid adenomas and multinodular goiters are the most common causes of endogenous subclinical hyperthyroidism. The LAB may be normal on retesting weeks or months later, so that intervention should not be considered unless persistently low TSH is noted.

Overt hyperthyroidism is associated with increased bone resorption, low bone density, and an increase in fracture. Patients with subclinical hyperthyroidism also have an increased risk of atrial fibrillation and have more subtle cardiac findings(increases in heart rate, cardiac contractility, and left ventricular mass). In patients at high risk for skeletal or cardiac complications, if the serum TSH <0.1 mU/L, we treat the underlying cause of subclinical hyperthyroidism. If the serum TSH is 0.1 to 0.5 mU/L, we suggest treatment if there is underlying cardiovascular disease or if the bone density is low or the radionuclide scan shows one or more focal areas of increased uptake. For patient with low risk for cardiac or skeletal complications with TSH <0.1 mU/L, we suggest treatment if the radionuclide scan shows one or more focal areas of increased uptake.

Thyroid echo was just preformed on 9/17. Microsomal Ab and TSHR Ab was negative then. There was no FNA data and it was not performed before(according to family statement). Thus, you may arranged aspiration cytology this time and recheck thyroid function later. However, the patient's will of invasive evaluation is not high. Please discusse with her and her family first.

Besides, Amiodarone may also cause mild Hyperthyroidism (3% to 10%). ARB may exaggerate CKD and induce hyperkalemia. Please evalute these drugs. You may also check ACTH and Cortisol, renin activity and aldosterone for hyperkalemia evalulation. Nephrologist may be consulted  if necessary.
read more

2014年12月11日 星期四

Hyperlupedemia

In patients with mild to moderate hypertriglyceridemia (150 to 500 mg/dL), the main indication for therapy is reduction of cardiovascular (CV) risk. Lifestyle changes are a central part of managing such patients. Pharmacologic therapy with statin therapy for CV risk reduction has been best proven.  Benefit from lowering the cholesterol with statins in patients without clinical evidence of CVD has also been demonstrated. Besides, glucocorticoids may cause peripheral insulin resistance, hyperinsulinemia, and increased VLDL synthesis.
read more

2014年12月9日 星期二

Suspected adrenal insufficency

Adrenal insufficiency is likely if the serum cortisol level is below 15 during critical condition or < 3 at 8:00 AM. Critically ill patients with established hypoadrenalism should be treated with hydrocortisone if no cintraindication. Ideally, a corticotropin test should be performed for diagnosis. If adrenal insufficiency is confirmed and ACTH levels are normal or high, further evaluation for mineralocorticoid deficiency should be performed (check PRA and aldosterone).
read more

2014年10月7日 星期二

Hyperthyroidism in pregnancy

Women with moderate to severe overt hyperthyroidism require treatment of hyperthyroidism. Thionamides are recommended. Available thionamides include propylthiouracil (PTU), methimazole (MMI), and carbimazole (CBZ), which is completely metabolized to MMI. All 3 antithyroid drugs (ATDs) have been associated with possible teratogenic effects. Compared with PTU, the effects are more common and more severe with MMI and CBZ.

Thyroid function should be monitored monthly to maintain serum free T4 concentrations in the high-normal range and serum TSH concentrations in the low-normal range. The dose of PTU should be limited to 50 mg twice daily or less becase higher doses may result in fetal goiter and hypothyroidism.
read more

2013年5月13日 星期一

Hyperkalemia




Tall peaked T waves with a shortened QT interval are usually the first findings

Progressive lengthening of the PR interval and QRS duration

P wave may disappear, and ultimately the QRS widens further to a sine wave pattern

Ventricular standstill with a flat line on the ECG ensues with complete absence of electrical activity.

Beta blockers interfere with the beta-2-adrenergic facilitation of potassium uptake by the cells, particularly after a potassium load. An increase in serum potassium is primarily seen with nonselective beta blockers (such as propranolol and labetalol). In contrast, beta-1-selective blockers such as atenolol have little effect on serum potassium since beta-2 receptor activity remains intact
read more

2013年1月16日 星期三

Coumardin interaction




MONITOR: Isoniazid may increase the anticoagulant effect of warfarin, perhaps by inhibition of warfarin metabolism. This effect has been reported with an isoniazid dose of 600 mg per day. Other oral anticoagulants may interact with isoniazid in a similar fashion. The proposed mechanism is inhibition of CYP450 2C9 hepatic metabolism by isoniazid.

MANAGEMENT: The patient's INR should be monitored, and the anticoagulant dosage should be adjusted if necessary, whenever isoniazid is initiated, discontinued or the dosage is changed. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bruising, red or brown urine, or red or black stools.


GENERALLY AVOID: Rifampin may decrease the anticoagulant effect of warfarin by enhancing CYP450 hepatic microsomal enzyme metabolism of warfarin.

MANAGEMENT: Concurrent use should be avoided unless no alternatives are available. The INR or prothrombin time should be monitored closely during concomitant therapy and after rifampin is discontinued. Adjustments in warfarin dosage may be needed when rifampin dosage is added, discontinued, or changed. This interaction may occur with other oral anticoagulants and with rifabutin.
read more